MDCO 2010

Drug Profile

MDCO 2010

Alternative Names: CU-2010; MDCO-2010

Latest Information Update: 27 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curacyte AG
  • Developer The Medicines Company
  • Class Antifibrinolytics; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Surgical blood loss

Most Recent Events

  • 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Germany (IV)
  • 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Switzerland (IV)
  • 01 Mar 2012 The Medicines Company initiates enrolment in a phase IIb trial in Surgical blood loss in Switzerland (NCT01530399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top